ArticleStatistics in biopharmaceutical research2020
Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19.
Article in Statistics in biopharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Characteristics, Progression, and Output of Randomized Platform Trials: A Systematic Review.JAMA network open · 2024Pooled it
- Systematic review of available software for multi-arm multi-stage and platform clinical trial design.Trials · 2021Pooled it
- Treating intrusive memories after trauma in healthcare workers: a Bayesian adaptive randomised trial developing an imagery-competing task intervention.Molecular psychiatry · 2023Trial
- Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.Nature reviews. Drug discovery · 2026Review
- Adaptive versus fixed designs in confirmatory clinical trials: centering the choice on ethics.Clinical trials (London, England) · 2026Article
- A Multi-Stage Drop-the-Loser Design With Superiority Boundaries.Statistics in medicine · 2026Article
- Adaptive trials in low back pain and osteoarthritis: How common are they and when should they be used? A systematic review from ClinicalTrials.gov.Osteoarthritis and cartilage open · 2026Review
- Article
- Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles.Statistics in medicine · 2026Article
- Drug Repurposing for Inclusion of COVID-19-Related Indication: Field Study of the European Medicines Agency's Response to the Pandemic.Pharmacy (Basel, Switzerland) · 2025Article
- Group-Sequential Designs With an Externally-Driven Change of Primary Endpoint.Statistics in medicine · 2025Article
- Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trials.BMC medicine · 2025Review
- Targeting the SARS-CoV-2 reservoir in long COVID.The Lancet. Infectious diseases · 2025Review
- Article
- A Preplanned Multi-Stage Platform Trial for Discovering Multiple Superior Treatments With Control of FWER and Power.Biometrical journal. Biometrische Zeitschrift · 2025Article
- Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century.Clinical and experimental immunology · 2025Review
- The Effect of Pomegranate Tea on the Clinical Outcomes and Symptom Alleviation in COVID-19 Patients: A Double-Blind Randomized Clinical Trial.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Innovative approaches for vaccine trials as a key component of pandemic preparedness - a white paper.Infection · 2024Review
- A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies.Statistical methods in medical research · 2024Article
- Bayesian sequential monitoring strategies for trials of digestive cancer therapeutics.BMC medical research methodology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the natural history of the disease and the number and characteristics of patients affected, and the emergence of new potential therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently strong evidence has been observed to answer the research question, without compromising the trial's scientific validity or integrity. In this article, we describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting. Our discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.